CCK-33 antagonizes apomorphine-induced growth hormone secretion and increases basal prolactin levels in man.
Cholecystokinin (CCK-33) (225 Ivy Dog Units intravenously) had no effect on basal growth hormone (GH) secretion but antagonized the GH response to the dopamine receptor agonist, apomorphine HCl (0.5 mg sc) (N = 7), and induced a transient increase in basal prolactin (PRL) secretion (N = 8) in normal men. These findings are similar to those described with neuroleptics and are compatible with an inhibitory effect of CCK-33, or fragments, on dopamine function in man, at least in the hypothalamic-pituitary axis. However, an inhibitory effect of CCK-33 on the release of GH and a stress-induced increase in PRL secretion cannot be excluded.
D000328:Adult; D001058:Apomorphine / Q000494:pharmacology*; D002766:Cholecystokinin / Q000494:pharmacology*; D004347:Drug Interactions; D013006:Growth Hormone / Q000378:metabolism*; D006801:Humans; D008297:Male; D011388:Prolactin / Q000378:metabolism*; D011954:Receptors, Dopamine / Q000378:metabolism; D013997:Time Factors
D011954:Receptors, Dopamine; D011388:Prolactin; D013006:Growth Hormone; D002766:Cholecystokinin; D001058:Apomorphine